Israel’s Oramed Granted Patent in Russia for Oral Administration of GLP-1


Oramed

Israeli startup Oramed Pharmaceuticals, a developer of oral drug delivery systems, has been granted by the Russian Federal Service for Intellectual Property a patent for its invention, titled “Methods and Compositions for Oral Administrations of Exenatide.”

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and is indicated for treatment of type 2 diabetes. Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss. Oramed’s oral GLP-1 capsule, based on the Company’s POD™ technology, could significantly increase compliance and become a valuable tool in the treatment of diabetes.

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the Company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition the Company is developing an oral GLP-1 analog capsule (ORMD-0901).

Read more about: , , , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems